Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration

Jenner, 2003, Oxidative stress in Parkinson's disease, Ann Neurol, 53, S26, 10.1002/ana.10483 Kutzing, 2008, Altered uric acid levels and disease states, J Pharmacol Exp Ther, 324, 1, 10.1124/jpet.107.129031 Pacher, 2007, Nitric oxide and peroxynitrite in health and disease, Physiol Rev, 87, 315, 10.1152/physrev.00029.2006 de la Torre, 1996, Human aging brain disorders: role of antioxidant enzymes, Neurochem Res, 21, 885, 10.1007/BF02532336 Cohen, 1974, The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by 6-hydroxydopamine, dialuric acid and related cytotoxic agents, J Biol Chem, 249, 2447, 10.1016/S0021-9258(19)42751-8 Cohen, 1984, Inhibition of free radical-induced DNA damage by uric acid, FEBS Lett, 174, 147, 10.1016/0014-5793(84)81094-7 Davies, 1986, Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid, Biochem J, 235, 747, 10.1042/bj2350747 Jellinger, 1999, The role of iron in neurodegeneration. Prospect for pharmacotherapy of Parkinson's disease, Drugs Aging, 14, 115, 10.2165/00002512-199914020-00004 Church, 1994, Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation, Brain Res Bull, 33, 419, 10.1016/0361-9230(94)90285-2 Duan, 2002, Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease, J Neurochem, 80, 101, 10.1046/j.0022-3042.2001.00676.x Davis, 1996, Observations on serum uric acid and the risk of idiopathic Parkinson's disease, Am J Epidemiol, 144, 480, 10.1093/oxfordjournals.aje.a008954 de Lau, 2005, Serum uric acid levels and the risk of Parkinson disease, Ann Neurol, 58, 797, 10.1002/ana.20663 Weisskopf, 2007, Plasma urate and risk of Parkinson's disease, Am J Epidemiol, 166, 561, 10.1093/aje/kwm127 Alonso, 2007, Gout and risk of Parkinson disease: a prospective study, Neurology, 69, 1696, 10.1212/01.wnl.0000279518.10072.df Gao, 2008, Diet, urate, and Parkinson's disease risk in men, Am J Epidemiol, 167, 831, 10.1093/aje/kwm385 De Vera, 2008, Gout and risk of Parkinson disease: a cohort study, Arthritis Rheum, 59, 1549, 10.1002/art.24193 Chen, 2009, Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) Study, Am J Epidemiol, 169, 1064, 10.1093/aje/kwp033 Annanmaki, 2007, Low plasma uric acid level in Parkinson's disease, Mov Disord, 22, 1133, 10.1002/mds.21502 Schwarzschild, 2008, Serum urate level as a predictor of clinical and radiographic progression of Parkinson's disease, Arch Neurol, 65, 716, 10.1001/archneur.2008.65.6.nct70003 Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 Movement Disorder Society task force on rating scales for Parkinson's disease. The unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov Disord 2003;18:738–50. Möller, 2005, Pharmacotherapy of Parkinson's disease in Germany, J Neurol, 252, 926, 10.1007/s00415-005-0784-1 Tohgi, 1993, The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease, J Neural Transm Park Dis Dement Sect, 6, 119, 10.1007/BF02261005 Schlesinger, 2008, Uric acid in Parkinson's disease, Mov Disord, 23, 1653, 10.1002/mds.22139 Schiess, 2008, Serum uric acid and clinical progression in Parkinson's disease. Potential biomarker for nigrostriatal failure, Arch Neurol, 65, 698, 10.1001/archneur.65.6.698 Bierer, 1982, Effect of l-Dopa on renalhandling of uric acid, J Pharmacol Exp Ther, 223, 55 Weiner, 2000, Is levodopa toxic?, Arch Neurol, 57, 408, 10.1001/archneur.57.3.408 Asanuma, 2005, Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro, Neurol Res, 27, 533, 10.1179/016164105X22093 Ogava, 1993, Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa, Adv Neurol, 60, 242 Ziv, 1997, Levodopa induces apoptosis in cultured neuronal cells—a possible accelerator of nigrostriatal degeneration in Parkinson's disease?, Mov Disord, 12, 17, 10.1002/mds.870120105 Zeevalk, 1998, Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism, J Neurochem, 70, 1421, 10.1046/j.1471-4159.1998.70041421.x Spencer, 1998, Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanism of formation involving reactive oxygen species, J. Neurochem, 71, 2112, 10.1046/j.1471-4159.1998.71052112.x Jones, 2000, Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differenciated PC12 cells, J Neurochem, 74, 2296, 10.1046/j.1471-4159.2000.0742296.x Pinheiro-Carrera, 1994, l-Dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation, Life Sci, 55, 991, 10.1016/0024-3205(94)00633-4 Kostrzewa, 2000, Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum, Amino Acids, 19, 183, 10.1007/s007260070049 Ischiropoulos, 1992, Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase, Arch Biochem Biophys, 298, 431, 10.1016/0003-9861(92)90431-U Good, 1998, Protein nitration in Parkinson's disease, J Neuropathol Exp Neurol, 57, 338, 10.1097/00005072-199804000-00006 Anderson, 2003, Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease, Free Rad Res, 37, 1131, 10.1080/10715760310001604134 Du, 2007, Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity, Glia, 55, 463, 10.1002/glia.20472 Spitsin, 2001, Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease, Mult Scler, 7, 313, 10.1177/135245850100700507 Mousavizadech, 2003, Uric acid: a novel treatment strategy for multiple sclerosis, Trends Pharmacol Sci, 24, 563, 10.1016/j.tips.2003.09.004 Scott, 2005, Uric acid protects against secondary damage after spinal cord injury, Proc Natl Acad Sci USA, 102, 3483, 10.1073/pnas.0500307102 Johnson, 2003, Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?, Hypertension, 41, 1183, 10.1161/01.HYP.0000069700.62727.C5 Hayden, 2004, Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle, Nutr Metab, 1, 10, 10.1186/1743-7075-1-10 Sautin, 2007, Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress, Am J Physiol Cell Physiol, 293, 584, 10.1152/ajpcell.00600.2006 Wise, 2008, Plasma urate and risk of Parkinson's disease, Am J Epidemiol, 167, 752, 10.1093/aje/kwn008 Rentzos, 2006, Serum uric acid and multiple sclerosis, Clin Neurol Neurosurg, 108, 527, 10.1016/j.clineuro.2005.08.004 Knapp, 2004, Serum uric acid levels in optic neuritis, Mult Scler, 10, 278, 10.1191/1352458504ms1042oa Kim, 2006, Decreased plasma antioxidants in patients with Alzheimer's disease, Int J Geriatr Psychiatry, 21, 344, 10.1002/gps.1469 Reynolds, 2007, Oxidative stress and the pathogenesis of neurodegenerative disorders, Int Rev Neurobiol, 82, 297, 10.1016/S0074-7742(07)82016-2 Drulovic, 2001, Uric acid levels in sera from patients with multiple sclerosis, J Neurol, 248, 121, 10.1007/s004150170246 Kean, 2000, The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood central nervous system barrier integrity, J Immunol, 165, 6511, 10.4049/jimmunol.165.11.6511